The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Pro-inflammatory tumor profile predicts PCR in NSCLC to neoadjuvant chemoimmunotherapy
Marta Casarrubios, MSc, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain, talks on an analysis into pre-treatment tumor samples of patients from the Phase II NADIM (NCT03081689) trial undergoing neoadjuvant chemoimmunotherapy. A pro-inflammatory tumor profile in the pre-treatment samples of patients with complete pathological response (CPR) was found. The pro-inflammatory tumor profile may predict an effective immune response to nivolumab. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
